Oncogene

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

Retrieved on: 
Monday, April 15, 2024
SLATE, Mutation, Safety, HLA, Trial of the century, National Cancer Institute, Vaccine, Gritstone bio, Human, Antigen presentation, BRAF, Oncogene, Patient, TP53, NCI, CTNNB1, Pharmaceutical industry

EMERYVILLE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine. The paper, “A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results,” describes a novel immunodominance hierarchy of tumor neoantigens (including KRAS) that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS, a “pure” KRAS-directed candidate that demonstrated superior immunogenicity to the initial version in a subsequent Phase 2 study and is currently being evaluated in a novel cell therapy-vaccine combination study run by Steven A. Rosenberg of the National Cancer Institute (NCT06253520).

Key Points: 
  • "Our team’s innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology.
  • Neoantigens were identified using Gritstone bio’s proprietary neoantigen prediction platform, EDGETM, and selected based on shared mutation and matched HLA frequencies in patient populations with solid tumors.
  • These data led to the development of SLATE-KRAS, a vaccine focused on KRAS-derived neoantigens that subsequently was evaluated in the Phase 2 portion of the clinical study.
  • Initial Phase 2 data suggesting an increased vaccine induced T cell response were presented in September 2022 ( press release ).

Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality

Retrieved on: 
Thursday, May 2, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, GV, Harvard University, Cancer, Genetics, Cell, Broad Institute, Survival, GV (company), Drug resistance, Growth, Overload, Oncogene, Patient, Neoplasm, NIBR, Investment, MIT, Pharmaceutical industry

Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.

Key Points: 
  • Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.
  • “Our activation lethality platform offers the potential for new cancer medicines that are effective on their own while also combating the emergence of resistance to classic targeted therapies.
  • Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality.
  • Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways.

Oncology Precision Medicine Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Pharmaceutical, Health, Oncology, Molecule, USD, Mortality, Radiation, Volunteering, Administration, Breast cancer, Cancer, Lung cancer, World Health Organization, Hub, Risk, Immunotherapy, Research, Genetic testing, Obesity, Disease, DNA, Therapy, Oncogene, Patient, Gastrointestinal cancer, Bone marrow, MD Anderson Cancer Center, Clinical trial, Medicine, Viral, Type, Interest, Mayo Clinic Cancer Center, Growth, Prevalence, Medical imaging

The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.

Key Points: 
  • The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.
  • Regional Analysis: North America Emerged as the Hub of Oncology Precision Medicine; Europe to be the Fastest Growing Market
    In 2024, North America is anticipated to capture close to 42% market share of the overall oncology precision medicine market.
  • In recent years, demand for oncology precision medicine has witnessed a tremendous increase in North America.
  • The oncology precision medicine market report presents an in-depth analysis of various precision medicine oncology companies in this domain, across different segments, as defined below:

Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Wednesday, April 3, 2024
Therapy, AACR, RNA, Oncogene

Aanastra, Inc., a biopharmaceutical company focused on developing novel RNA therapeutics targeting Tumor Suppressors and Oncogenes, today announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.

Key Points: 
  • Aanastra, Inc., a biopharmaceutical company focused on developing novel RNA therapeutics targeting Tumor Suppressors and Oncogenes, today announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.
  • AACR poster presentation details are below:
    Title: " Selective deletion of the KRAS mutant gene with ADGN-121 and ADGN-122 peptide-RNA nanoparticles: A new strategy to overcome acquired resistance to KRASG12C and KRASG12D small molecule inhibitors "

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on: 
Wednesday, April 3, 2024
Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points: 
  • Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
  • The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
  • In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
  • As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and ​comprehensive, genome-wide analysis.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

Retrieved on: 
Sunday, April 7, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, SOC, Melanoma Research, Oncogene, RNA-binding protein, Patient, SVP, Neoplasm, RNA, Cancer, Messenger, Melanoma, Lung cancer, Society, IND, Immortalised cell line, AACR, Breast cancer, RBP, Therapy, Translational medicine, Vaccine

These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .

Key Points: 
  • These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
  • eIF4E is a main regulator and rate limiting factor for protein synthesis and is elevated in many kinds of tumors.
  • Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC.
  • “The ability to target RNA-binding proteins that regulate oncogenes is a powerful modality with the potential to address cancer indications with high unmet need.

Dr. Laura Shawver to be Recognized as 2024 Duane Roth Endowed Award Lecture Recipient at 20th Annual Industry/Academia Precision Oncology Symposium

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, Consumer, Women, Science, Biotechnology, Diagnosis, Ovarian cancer, Cell, Disease, Oncogene, UC, Research, Cancer, Messenger, Woman, Therapy, Cytokine, AAA, Pharmaceutical industry

The Duane Roth Endowed Lecture Committee today announced that it will recognize Laura Shawver, Ph.D., as the 2024 Award Lecture recipient.

Key Points: 
  • The Duane Roth Endowed Lecture Committee today announced that it will recognize Laura Shawver, Ph.D., as the 2024 Award Lecture recipient.
  • The award will be presented by San Diego Mayor Todd Gloria during the 20th Annual Industry/Academia Precision Oncology Symposium on March 21 in La Jolla, California.
  • Dr. Laura Shawver is a healthcare pioneer who has created new paradigms in cancer research and treatment through her roles as a scientist, leader, patient and patient advocate.
  • As an early career scientist, she conducted research on oncogenes, growth factors and signal transduction pathways.

Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs

Retrieved on: 
Thursday, April 4, 2024
Partner, EGFR, Oncogene, Partnership, RAS, Patient, Research, Aethon, Publication, Neoplasm, Therapy, BTK, Immune system, Apple tree, Pharmaceutical industry

NEW YORK, April 4, 2024 /PRNewswire/ -- Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, today announced that it has entered into a collaboration agreement with Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers. Under the terms of the agreement, Aethon will use its HapImmune™ platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines' RAS(ON) inhibitors, with the goal of fueling tumor clearance and helping to establish immune memory.

Key Points: 
  • The terms of the agreement provide for a multi-year collaboration under which Aethon is responsible for conducting preclinical work, with full reimbursement by Revolution Medicines.
  • Revolution Medicines has an option to conduct any clinical development of products that may arise from the collaboration.
  • The arrangement provides for both upfront and potential downstream payments covering future development and commercialization activities should Revolution Medicines exercise its option.
  • Beyond the programs being advanced in partnership with Revolution Medicines, Aethon has additional programs targeting validated covalent small molecules that inhibit RAS, EGFR, and BTK.

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

Retrieved on: 
Thursday, March 21, 2024
B cell, Oncogene, Tissue, Research, Tumor microenvironment, Cell membrane, University, Genomics, Escape Room, Medical imaging

PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.

Key Points: 
  • PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications.
  • These new products expand the breadth of the Xenium single cell spatial analysis menu.
  • The Xenium In Situ Cell Segmentation Kit improves the determination of cell boundaries by using a stain and algorithmic technique developed and validated through custom-trained machine learning models.
  • State-of-the-art, custom-built algorithm: Obtain more accurate cell segmentation with an advanced AI algorithm specifically trained on real-world Xenium cellular and tissue data.